Sequent Scientific Limited has submitted to the Exchange, the financial results for the period ended March 31, 2025.
VIYASH · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
SeQuent Scientific Limited reported a strong turnaround in FY25, with consolidated revenue rising about 13% to ₹15,513.7 million (from ₹13,697.3 million in FY24) and consolidated profit after tax swinging to ₹322.6 million from a loss of ₹296.2 million in the previous year. On a standalone basis, revenue grew roughly 6% to ₹1,782.6 million and PAT jumped to ₹158 million from just ₹6.3 million, with EPS rising to ₹0.63 from ₹0.03. Q4FY25 consolidated revenue grew 11% year-on-year to ₹4,017 million, with PAT of ₹103.8 million. The Board has not recommended any dividend for FY25 and appointed BMP & Co. LLP as the new Secretarial Auditor for five years from FY26. A composite scheme of amalgamation involving group entities (including Viyash Life Sciences, Symed Labs, and others) approved earlier remains pending regulatory approvals.
The sharp swing from consolidated loss to profit and healthy revenue growth signal a clear operational turnaround, which is positive for shareholders, though the absence of a dividend and pending amalgamation create some uncertainty around capital return and corporate structure.